<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00731042</url>
  </required_header>
  <id_info>
    <org_study_id>I2MS05-010877</org_study_id>
    <nct_id>NCT00731042</nct_id>
  </id_info>
  <brief_title>A Two-week Crossover Evaluation of Two Hand Antiseptic Products on Skin Condition in Healthy Human Subjects</brief_title>
  <official_title>A Two-week Crossover Evaluation of Two Hand Antiseptic Products on Skin Condition in Healthy Human Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>3M</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>3M</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the effect of two hand antiseptic products on hand skin conditions of healthy
      volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Skin Health, Visual Skin Score (VSS) at 14 Days</measure>
    <time_frame>Baseline and 14 days</time_frame>
    <description>Observe VSS score at 14 days, and graded change of skin health from baseline using scale of 0 (normal) - 5 (very scaly).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Avagard</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3M Avagard Surgical and healthcare Personnel Hand Antiseptic with Moisturizers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Purell</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Purell Surgical Scrub with Moisturizers</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avagard</intervention_name>
    <description>Topical solution, 6 mL, 6 applications/day for 14 days.</description>
    <arm_group_label>Avagard</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Purell Surgical Scrub</intervention_name>
    <description>Topical solution, 4 mL, 6 applications/day for 14 days.</description>
    <arm_group_label>Purell</arm_group_label>
    <other_name>Purell Surgical Scrub with Moisturizers</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female age 25 - 55

          -  Subject agrees not to use any hand wash products on their hands other than what has
             been provided in the study.

          -  Subject agrees not to use any moisturizers or any skin products on their hands during
             the study

          -  Subject agrees to use gloves to protect hands from activities such as dish washing

          -  Subject is willing to sign the Informed Consent and HIPAA

          -  Subject agrees to comply with the study requirement

        Exclusion Criteria:

          -  Subject has a history of psoriasis, active dermatitis, skin reactions, cracked,
             irritated, broken skin, skin infection on their hands

          -  Subject has scaly skin on hands based on Visual Scoring Scale at Day 1

          -  Subject has a sensitivity or history of skin reactions to any study materials (eg,
             alcohol, chlorhexidine gluconate or zinc pyrithone or latex in the gloves)

          -  Subject has been using moisturizing products or any products on their arms and hands
             within 5 days prior to participation in the study

          -  Subject is pregnant

          -  Study coordinator believes the subject is unsuitable for inclusion in the study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary L Grove, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>cyberDERM Clinical Research</affiliation>
  </overall_official>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2008</study_first_submitted>
  <study_first_submitted_qc>August 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2008</study_first_posted>
  <results_first_submitted>January 23, 2009</results_first_submitted>
  <results_first_submitted_qc>June 16, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 17, 2009</results_first_posted>
  <last_update_submitted>January 24, 2012</last_update_submitted>
  <last_update_submitted_qc>January 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Skin health</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Skin Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Infective Agents, Local</mesh_term>
    <mesh_term>Chlorhexidine gluconate</mesh_term>
    <mesh_term>Chlorhexidine</mesh_term>
    <mesh_term>Hand Sanitizers</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>After screening, there was a 5-days washout prior to enrollment into period 1. This was then followed by another 5-days washout between periods 1 and 2.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Purell First Followed by Avagard</title>
          <description>Using Purell for 14 days. Rest for 5 days(no product used). Then use Avagard for 14 days.</description>
        </group>
        <group group_id="P2">
          <title>Avagard First Followed by Purell</title>
          <description>Using Avagard for 14 days. Rest for 5 days(no product used). Then use Purell for 14 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Wash-out</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="15">2 subjects did not met inclusion criteria for Period 2 Visual scoring skin condition</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not meet inclusion criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Purell First Followed by Avagard</title>
          <description>Using Purell for 14 days. Rest for 5 days(no product used). Then use Avagard for 14 days.</description>
        </group>
        <group group_id="B2">
          <title>Avagard First Followed by Purell</title>
          <description>Using Avagard for 14 days. Rest for 5 days(no product used). Then use Purell for 14 days.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="33"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Skin Health, Visual Skin Score (VSS) at 14 Days</title>
        <description>Observe VSS score at 14 days, and graded change of skin health from baseline using scale of 0 (normal) - 5 (very scaly).</description>
        <time_frame>Baseline and 14 days</time_frame>
        <population>Analysis was done per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Purell First Followed by Avagard</title>
            <description>Using Purell for 14 days. Rest for 5 days(no product used). Then use Avagard for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Avagard First Followed by Purell</title>
            <description>Using Avagard for 14 days. Rest for 5 days(no product used). Then use Purell for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Skin Health, Visual Skin Score (VSS) at 14 Days</title>
          <description>Observe VSS score at 14 days, and graded change of skin health from baseline using scale of 0 (normal) - 5 (very scaly).</description>
          <population>Analysis was done per protocol</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="1.11"/>
                    <measurement group_id="O2" value="0.4" spread="1.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The number of participants affected/at risk in the adverse event reporting section was recorded as &quot;0&quot;. Adverse events and Serious adverse events were collected and assessed, but none observed.</desc>
      <group_list>
        <group group_id="E1">
          <title>Purell First Followed by Avagard</title>
          <description>Using Purell for 14 days. Rest for 5 days(no product used). Then use Avagard for 14 days.</description>
        </group>
        <group group_id="E2">
          <title>Avagard First Followed by Purell</title>
          <description>Using Avagard for 14 days. Rest for 5 days(no product used). Then use Purell for 14 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PI was a test lab, and they do not publish study result. Sponsor can choose to publish.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chou Eyberg</name_or_title>
      <organization>3M Company</organization>
      <phone>651-737-0934</phone>
      <email>cieyberg1@mmm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

